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Abstract
IMPORTANCE—Myasthenia gravis is a chronic, autoimmune, neuromuscular disease 
characterized by fluctuating weakness of voluntary muscle groups. Although genetic factors are 
known to play a role in this neuroimmunological condition, the genetic etiology underlying 
myasthenia gravis is not well understood.
OBJECTIVE—To identify genetic variants that alter susceptibility to myasthenia gravis, we 
performed a genome-wide association study.
DESIGN, SETTING, AND PARTICIPANTS—DNA was obtained from 1032 white individuals 
from North America diagnosed as having acetylcholine receptor antibody–positive myasthenia 
gravis and 1998 race/ethnicity-matched control individuals from January 2010 to January 2011. 
These samples were genotyped on Illumina OmniExpress single-nucleotide polymorphism arrays. 
An independent cohort of 423 Italian cases and 467 Italian control individuals were used for 
replication.
MAIN OUTCOMES AND MEASURES—We calculated P values for association between 
8114394 genotyped and imputed variants across the genome and risk for developing myasthenia 
gravis using logistic regression modeling. A threshold P value of 5.0 × 10−8 was set for genome-
wide significance after Bonferroni correction for multiple testing.
RESULTS—In the over all case-control cohort, we identified association signals at CTLA4 
(rs231770; P = 3.98 × 10−8; odds ratio, 1.37; 95% CI, 1.25–1.49), HLA-DQA1 (rs9271871; P = 
1.08 × 10−8; odds ratio, 2.31; 95% CI, 2.02 – 2.60), and TNFRSF11A (rs4263037; P = 1.60 × 
10−9; odds ratio, 1.41; 95% CI, 1.29–1.53). These findings replicated for CTLA4 and HLA-DQA1 
in an independent cohort of Italian cases and control individuals. Further analysis revealed distinct, 
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but overlapping, disease-associated loci for early- and late-onset forms of myasthenia gravis. In 
the late-onset cases, we identified 2 association peaks: one was located in TNFRSF11A 
(rs4263037; P = 1.32 × 10−12; odds ratio, 1.56; 95% CI, 1.44–1.68) and the other was detected in 
the major histocompatibility complex on chromosome 6p21 (HLA-DQA1; rs9271871; P = 7.02 × 
10−18; odds ratio, 4.27; 95% CI, 3.92–4.62). Association within the major histocompatibility 
complex region was also observed in early-onset cases (HLA-DQA1; rs601006; P = 2.52 × 10−11; 
odds ratio, 4.0; 95% CI, 3.57–4.43), although the set of single-nucleotide polymorphisms was 
different from that implicated among late-onset cases.
CONCLUSIONS AND RELEVANCE—Our genetic data provide insights into aberrant cellular 
mechanisms responsible for this prototypical autoimmune disorder. They also suggest that clinical 
trials of immunomodulatory drugs related to CTLA4 and that are already Food and Drug 
Administration approved as therapies for other autoimmune diseases could be considered for 
patients with refractory disease.
Autoimmune myasthenia gravis is a disorder of neuro-muscular transmission clinically 
characterized by muscle fatigability manifested by diplopia, ptosis, and bulbar and limb 
weakness.1,2 The disorder is typically mediated by antibodies against nicotinic acetylcholine 
receptors (AChRs) or against related proteins located at the neuromuscular junction such as 
muscle-specific tyrosine kinase (MuSK), lipoprotein receptor–related protein 4, and 
agrin.1–4 Although myasthenia gravis is relatively uncommon, the apparent incidence has 
increased in the white population over time owing, at least in part, to improved recognition 
of the disorder among elderly individuals.5 Acute respiratory failure requiring mechanical 
ventilation (myasthenic crisis) occurs in up to 20% of patients and is associated with 
significant morbidity and mortality.6,7
There is increasing recognition that myasthenia gravis is not a monolithic disease.8,9 
Epidemiological studies have shown a bimodal pattern of incidence, with early-onset cases 
(defined as initial symptoms occurring before age 40 years) being predominantly women 
and late-onset patients being mostly men.9–11 Advanced age is associated with an increased 
response to autoantigens, although the implications of the age- and sex-specific frequency 
distribution of myasthenia gravis regarding pathogenesis remain unclear.10,12
Genetic factors contribute to the susceptibility to develop myasthenia gravis. Identified more 
than 30 years ago, the human leukocyte antigen (HLA) locus remains the most strongly 
associated risk factor for the disease.9,13,14 A genome-wide association study (GWAS) 
involving 649 early-onset cases drawn from the Scandinavian, British, French, Dutch, 
German, and American populations identified variants in the major histocompatibility 
complex (MHC) class II locus, protein tyrosine phosphatase nonreceptor type 22 (PTPN22), 
and TNFAIP3 interacting protein 1 (TNIP1).15 The cytotoxic T-lymphocyte–associated 
protein 4 gene (CTLA4) has also been previously suggested as a susceptibility factor for 
myasthenia gravis based on candidate gene studies.16 Furthermore, patients with myasthenia 
gravis frequently have a personal or family history of other autoimmune disorders, most 
notably autoimmune thyroid disease, rheumatoid arthritis, and type 1 diabetes mellitus,17,18 
although the genetic basis underlying this predisposition to autoimmunity is unknown. 
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Finally, approximately 5% of patients report a family history of myasthenia gravis that 
usually follows an autosomal dominant pattern of inheritance.14,19
To identify susceptibility loci operating in AChR antibody–positive myasthenia gravis, we 
undertook a GWAS of 1032 patients diagnosed as having myasthenia gravis (case cohort) 
and 1998 neurologically normal individuals (control cohort) using Illumina 
HumanOmniExpress Beadchips.
Methods
Samples
From January 2010 to January 2011, DNA was collected from patients attending myasthenia 
gravis clinics at 14 centers throughout North America using Oragene DNA Saliva Collection 
kits (DNA Genotek Inc). All patients included in the case cohort had been diagnosed by a 
neurologist specializing in myasthenia gravis, had onset of symptoms after age 18 years, and 
were of non-Hispanic white race/ethnicity (eTable 1 in the Supplement). The diagnosis of 
myasthenia gravis was based on standard clinical criteria of characteristic weakness, fatigue, 
and electrophysiological and/or pharmacological abnormalities,1 and it was confirmed by 
the presence of anti-AChR antibodies.20 Patients with positive test results for antibodies to 
muscle-specific kinase (anti-MuSK) were excluded from enrollment.21 For the control 
cohort, we downloaded genotype data from dbGAP (http://www.ncbi.nlm.nih.gov/gap; 
phs000196.v2.p1) for 1998 US neurologically normal individuals. The control cohort was 
matched to the case cohort for race/ethnic group but not for age or sex.
The replication cohort consisted of DNA obtained from 423 Italian patients diagnosed as 
having AChR-positive myasthenia gravis and 467 Italian neurologically normal control 
individuals (eTable 1 in the Supplement). Blood samples were collected from January 2010 
to January 2011 at the Catholic University Rome and at Cisanello Hospital, Pisa, Italy. The 
control cohort was matched to the case cohort for race/ethnic group but not for age or sex.
Written consent was obtained from all patients enrolled in this study. Institutional review 
board approval was obtained at all participating institutions including Johns Hopkins 
University and the National Institute on Aging.
Genome-wide Genotyping
The case cohort was genotyped in the Laboratory of Neurogenetics, National Institute on 
Aging, using HumanOmniExpress BeadChips (Illumina), which assay 730 525 single 
nucleotide polymorphisms (SNPs) across the genome. Individual-level genotypes for the 
myasthenia gravis case cohort are available on the dbGAP web portal (phs000726.v1.p1). 
The control cohort had been previously genotyped at the Center for Inherited Disease 
Research at Johns Hopkins University on HumanOmni1-Quad BeadChips (Illumina) as part 
of a GWAS of Parkinson disease.22 Analyses were confined to the 677 673 autosomal SNPs 
that were common to both chips.
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Genotyping Assays in the Replication Cohort
Rs231770, rs4263037, and rs9270986 were analyzed using Taqman genotyping assays and 
scanned on an ABI 7900HT Real-Time polymerase chain reaction system (Applied 
Biosystems) according to the manufacturer’s protocol. Rs601006 and rs9271850 in the 
MHC region were analyzed by sequencing using the Big-Dye Terminator version 3.1 
sequencing kit (Applied Biosystems), run on an ABI 3730xl DNA analyzer, and analyzed 
with Sequencher software (version 4.2; Gene Codes) and Mutation Surveyor (version 4.0.9; 
Softgenetics). Primers and polymerase chain reaction conditions are listed in eTable 2 in the 
Supplement.
Genomic DNA from the Italian replication cohort was used for the Taqman assays. Owing to 
low quantities, the remaining genomic DNA was amplified using the REPLI-g kit according 
to the manufacturer’s protocol (Qiagen), and the amplified DNA was used in the Sanger 
sequencing experiments.
Statistical Analysis
Genome-wide Association
Statistical analyses were performed using R statistical software (version 2.15.2).23 We 
applied standard quality-control procedures to the data: exclusion of samples with SNP call 
rates of less than 95%, non-European ancestry, or cryptic relatedness defined as identity-by-
descent proportion of inheritance (pi_hat from the PLINK software toolset version 1.0624) 
greater than 0.1, as well as exclusion of SNPs with call rates of less than 95%, minor allele 
frequency less than 0.01 in the control cohort, and Hardy-Weinberg equilibrium P < .001 in 
the control cohort. The cryptic-relatedness threshold led to the exclusion of individuals who 
shared more than 10% of their genome, which meant that related individuals down to third- 
or fourth-degree relatives were not included in the final analysis. The index individual whose 
sample had the better call rate from each related pair was excluded from the analysis (17 
related pairs).
After quality control, we used a Markov chain–based Haplotyper (version 1.0.16) to impute 
genotypes for all participants.25 A total of 8 114 394 SNPs (consisting of 513 081 genotyped 
SNPs and 7 601 313 imputed SNPs) were available for analysis.
We calculated P values using logistic regression modeling incorporating the first 2 principal 
components as covariates to compensate for any residual population stratification. Principal 
components were generated using Genome-wide Complex Trait Analysis software package 
implementation of eigenstrat.26 A threshold of 5.0 × 10−8 was set for genome-wide 
significance after Bonferroni correction for multiple testing.27
Probability Analysis and Heritability Estimates
We used density estimation to generate posterior probabilities of developing myasthenia 
gravis based on age and sex.
The Genome-wide Complex Trait Analysis package uses covariance matrices and mixed 
modeling to estimate the heritability of a trait in an ostensibly outbred population.26,28,29 We 
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applied this method to compare each case series (all cases, early-onset cases, and late-onset 
cases) to all control individuals. For each model, we compared 2 separate subsets of SNPs, 
one inclusive of all genotyped SNPs and another including only SNPs within ±1 MB from 
the loci identified as genome-wide significant in the discovery phase of analyses (Table 1). 
Only SNPs and samples passing quality control were used to evaluate the heritability and all 
analyses were adjusted for population substructure by using C1 and C2 from principle 
component analysis as covariates. Further details are provided in the eAppendix in the 
Supplement.
Results
GWAS Identifies Loci Influencing Risk for Myasthenia Gravis
After imputation and quality-control measures, 8 114 394 genotyped and imputed SNPs 
from 972 North American patients diagnosed as having AChR antibody–positive myasthenia 
gravis and 1977 North American control individuals were available for analysis. Quartile-
quartile plots did not show evidence of significant population stratification (Figure 1A; 
genomic inflation factor λ = 1.036).
In addition to the previously reported MHC class II region signal near the MHC class II DQ 
α 1 (HLA-DQA1) gene,30 we observed a strong association signal on chromosome 2q33 in 
the CTLA4 locus with a P value that reached genome-wide significance (rs231770; P = 3.98 
× 10−8; odds ratio [OR], 1.37; 95% CI, 1.25–1.49; Figure 1B). We also identified a strong 
association peak on chromosome 18q21.33 within the tumor necrosis factor receptor 4 
superfamily, member 11a, NFKB activator (TNFRSF11A) gene (rs4263037; P = 1.60 × 
10−9; OR, 1.41; 95% CI, 1.29–1.53). Markers that achieved genome-wide significance in the 
analysis of the whole cohort are shown in Table 1, and SNPs associated at P < 1.0 × 10−6 are 
listed in eTable 3 in the Supplement.
Early- and Late-Onset Myasthenia Gravis Possess Distinct Genetic
Architecture Density estimate plots confirmed a bimodal sex distribution within our case 
cohort, with myasthenia gravis being more common in younger women and older men 
(Figure 1C). To elucidate the genetic architecture underlying this age difference, we 
performed GWAS of early-onset cases (235 cases with onset at age <40 years and 1977 
control individuals) and late-onset cases (737 cases with onset at age >40 years and 1977 
control individuals). The TNFRSF11A and HLA-DQA1 association signals were 
significantly enhanced among late-onset cases (rs4263037, P = 1.32 × 10−12; OR, 1.56; 95% 
CI, 1.44–1.68 and rs9271871, P = 7.02 × 10−18; OR, 4.27; 95% CI, 3.92–4.62, respectively; 
Figure 1D; Table 1). In contrast, there was no evidence of association within TNFRSF11A 
in the young-onset cases (rs4263037; P = .83; Figure 1E). Furthermore, although an 
association signal was present near HLA-DQA1 in the younger patients, the most 
significantly associated SNPs were different compared with those observed in the late-onset 
cohort (rs601006; P = 2.52 × 10−11; OR, 4.0; 95% CI, 3.57–4.43; eTables 4 and 5 in the 
Supplement).
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Myasthenia Gravis Risk Loci Replicated in an Independent Cohort We selected 3 SNPs from 
the risk loci identified on chromosomes 2, 6, and 18 in the overall cohort for genotyping in 
an independent replication collection consisting of 423 Italian AChR antibody–positive 
myasthenia gravis cases and 467 Italian control individuals. We found the strongest signals 
at rs9270986 in the intergenic region between HLA-DRB1 and HLA-DQA1 and at rs231770 
located 3.3 kb upstream of CTLA4 (Figure 2A and B). In a combined analysis, we 
integrated the US GWAS and the Italian replication data using fixed effects modeling. Two 
loci (CTLA4 and HLA-DQA1) were associated with myasthenia gravis at genome-wide 
significance (P = 9.25 × 10−11 and 6.17 × 10−8, respectively; Table 1).
We also attempted to replicate the most highly associated SNPs observed in the early- and 
late-onset cases using the same Italian replication collection. Rs601006 near HLA-DQA1 
was significantly associated among early-onset cases (169 Italian myasthenia gravis cases 
and 467 control individuals; P = 5.53 × 10−5; Table 1; Figure 2C). This SNP was not 
associated among late-onset cases (250 cases and 467 control individuals; P = .22), 
recapitulating the pattern observed in the discovery cohort.
Similarly, we replicated the SNPs observed near HLA-DQA1 and within TNFRSF11A in 
the late-onset cases. Rs9271850 near HLA-DQA1 was significantly associated in the late-
onset Italian cohort (P = 8.15 × 10−4; Table 1; Figure 2D) but was not associated among the 
early-onset cases (P = .53). Rs4263037 located on chromosome 18 showed a trend toward 
significance (P for patients aged ≥40 years at symptom onset = .09; Figure 2E). This SNP 
became progressively more associated with increasing age of the replication cohort (P for 
patients aged ≥50 years at symptom onset = .04; P for patients aged ≥ 70 years = 8.75 × 
10−3).
Myasthenia Gravis Is Highly Heritable
The relative importance of genetic factors in a complex disease like myasthenia gravis can 
be estimated by quantifying heritability. We generated heritability estimates for AChR 
antibody–positive myasthenia gravis using a sophisticated algorithm (Genome-wide 
Complex Trait Analysis) that analyzes all of the genome-wide SNPs simultaneously (Table 
2). Our genotype data accounted for 25.6% (95% CI, 18.6–32.6) of the phenotype variance 
observed in all myasthenia gravis cases. Analysis of more precise phenotypes (early- and 
late-onset cases) generated even higher estimates of heritability (37.9%; 95% CI, 16.8–59.0 
and 35.3%; 95% CI, 27.1–43.5, respectively). These estimates are substantially higher than 
heritability identified using genome-wide–associated SNPs alone (1%–3%), indicating that 
additional risk loci remain to be identified.
DISCUSSION
Our GWAS of AChR antibody–positive myasthenia gravis identified several new loci that 
drive susceptibility to develop disease. We also provide strong evidence that early- and late-
onset myasthenia gravis have distinct, but overlapping, genetic architecture, thereby 
confirming previous epidemiological and clinical data suggesting a division between these 2 
forms of disease. Genetic variation within the TNFSRF11A locus drives susceptibility to 
disease only among older cases, whereas different haplotypes across the same HLA region 
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on chromosome 6 were identified in early- and late-onset cases. CTLA4 exerts a significant 
effect regardless of age at symptom onset, suggesting that it plays a central role in 
generating the aberrant autoimmune response that leads to neuromuscular junction 
dysfunction.
CTLA4 is a 45-kD immunoglobulin protein expressed by activated T cells and sharing 
significant sequence identity with CD28 (Figure 2F). CTLA4 increases T-cell motility and 
reduces contact periods between T cells and antigen-presenting cells leading to decreased 
cytokine production and proliferation. In this way, CTLA4 is thought to down-regulate T-
cell activation, terminate T-cell responses, and protect against autoimmunity.31 CTLA4-
deficient mice have high serum immunoglobulin concentrations and develop massive 
lymphocyte infiltration of lymph nodes and spleen, suggesting that CTLA4 plays an 
inhibitory role in regulating lymphocyte expansion.32 The mechanism of CTLA4’s 
regulatory action is controversial; however, evidence suggests that cells expressing CTLA4 
avidly endocytose the co-stimulatory factors CD80 and CD86 on antigen-presenting cells 
and degrade them.33 Genetic variant in the CTLA4 locus has been implicated in other 
autoimmune disorders including celiac disease,34 type 1 diabetes mellitus,35 thyroiditis,36 
and rheumatoid arthritis.37 Indeed, abatacept and belatacept are commercially available 
proteins consisting of CTLA4 rendered soluble by fusion to antibodies (CTLA4-IgG) 
approved for use in the treatment of refractory rheumatoid arthritis38 and as first-line 
immunosuppressants for renal transplant patients immune to Epstein-Barr virus.39 Clinical 
trials of these agents are also under way in inflammatory bowel disease, systemic lupus 
erythematosus, and other autoimmune diseases. They have not previously been used 
therapeutically in myasthenia gravis, although our experimental studies demonstrated the 
effectiveness of CTLA4-Ig in the treatment of rats with experimental autoimmune 
myasthenia gravis.40,41
Genetic analysis of additional case-control cohorts will be required to confirm the 
association observed for the TNFRSF11A locus. Nevertheless, the pattern of association 
uncovered for this locus, with a large effect in late-onset disease that is absent in younger 
patients, led us to speculate that age-related changes in local gene expression predispose 
toward an aberrant immune response to autoantigens. TNFRSF11A encodes the 4.5-kDa 
receptor activator of nuclear factor-κ B expressed on the surface of antigen-presenting 
dendritic cells.42 This receptor is an important regulator of the interaction between T cells 
and dendritic cells that is essential for immune surveillance and the regulation of specific 
immunity.42 Furthermore, TNFRSF11A is critical for lymph node organogenesis and 
osteoclast differentiation.43 Mutations in this gene are responsible for a form of familial 
Paget disease of the bone44 and for autosomal recessive osteopetrosis associated with 
defective immunoglobulin production.45 Receptor activator of nuclear factor-κ B knockout 
mice also have profound osteopetrosis resulting from a complete lack of osteoclasts, as well 
as near total absence of peripheral lymph nodes.43,45
The association signal that we identified in the MHC region was distinct from that reported 
by Gregersen et al15 to increase susceptibility for myasthenia gravis. Furthermore, our study 
did not show any evidence of association in the PTPN22 or TNIP1 loci found by the same 
study (eTable 6 in the Supplement).15 These disparities likely arise from differences in the 
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populations studied. In their study, patients and control individuals from 7 countries were 
included.15 Such population stratification impedes the identification of true association and 
increases the rate of false-positive association46 particularly in the HLA region that is known 
to be highly divergent across races/ethnicities.47 In contrast, we attempted to reduce clinical 
heterogeneity by selecting only cases from North America for the discovery cohort and from 
Italy for the replication cohort.
We considered the possibility that our study may have had population stratification, 
especially because we used an outbred American population as our original discovery 
cohort. The lack of age and sex matching of control samples to cases also may have 
introduced artifacts into our analysis. To avoid this, we applied strict filters to exclude 
outlying samples and incorporated principal components generated from the genome-wide 
data into the analysis model to compensate for residual population stratification between 
case and control samples. Furthermore, we replicated our results in a case-control cohort 
drawn from a distinct single population and found identical patterns of association among 
early- and late-onset cases.
Heritability can be considered the proportion of a disease that arises from genetics. Prior 
studies have estimated that only between 3.8% and 7.1% of individuals who receive a 
diagnosis of myasthenia gravis have a family history of disease.14,48 The genome-wide 
nature of our data set yielded a higher estimate of the heritability associated with myasthenia 
gravis risk by capturing more of the polygenic variance. This pattern is consistent with other 
neurological diseases, such as amyotrophic lateral sclerosis and Parkinson disease, where 
heritability estimates are significantly higher than the rate of familial disease.49,50 
Furthermore, our heritability estimates suggest that there are genetic factors contributing to 
the disease that have yet to be identified and that GWASs involving larger cohorts will yield 
additional loci. To that end, we have made our raw genotype data publicly available on 
dbGaP to facilitate meta-analysis with existing and future studies.
A strength of our study was that genetic analysis was confined to patients diagnosed as 
having AChR antibody– positive myasthenia gravis. This approach decreased disease 
heterogeneity and improved the power of the study to identify association signals. 
Approximately 85% of patients with myasthenia gravis have detectable AChR antibodies 
and approximately 40% of the remainder are MuSK antibody positive.2,51,52 Furthermore, 
AChR antibody–negative myasthenia gravis is less common among elderly individuals,52 
and MuSK-positive patients are more like to be women.53 In light of this, care should be 
taken in generalizing our results to the AChR antibody–negative myasthenia gravis 
population. Nevertheless, our data support the existence of distinct, but overlapping, genetic 
profiles for patients with early- and late-onset myasthenia gravis with detectable AChR 
antibodies.
Conclusions
Our GWAS identified susceptibility loci for AChR antibody– positive myasthenia gravis at 
CTLA4, HLA-DRB1/HLA-DQA1, and TNFRSF11A, and it showed distinct, but 
overlapping, genetic risk factors underlying early- and late-onset disease. Although future 
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studies involving deep resequencing of these loci will be required to identify the functional 
variants underlying these association signals, our data also suggest that clinical trials of 
CTLA4 immunomodulatory therapies could be considered in patients with myasthenia 
gravis with refractory disease failing to respond to standard therapies.
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Figure 1. Myasthenia Gravis Cases and P Values From the Genome-Wide Association Study of 
Myasthenia Gravis
A, Quartile-quartile plot showing the distribution of expected vs observed P values for the 
US discovery cohort (972 myasthenia gravis cases and 1977 control individuals; λ = 1.036). 
B, Manhattan plot of genome-wide association results for all myasthenia gravis cases (972 
cases and 1977 control individuals). C, Density plot of myasthenia gravis cases (n = 972) 
showing bimodal frequency distribution with disease being more common in younger 
women and older men. D, Plot of genome-wide association results for late-onset myasthenia 
gravis cases (737 cases and 1977 control individuals). E, Plot of genome-wide association 
results for early-onset myasthenia gravis cases (235 cases and 1977 control individuals). 
CTLA4 indicates cytotoxic T-lymphocyte–associated protein 4; HLA, human leukocyte 
antigen; and TNFRSF11A, tumor necrosis factor receptor 4 superfamily, member 11a, 
NFKB activator gene. The orange horizontal line depicts the Bonferroni-adjusted 
significance threshold (5.0 × 10−8). Single-nucleotide polymorphisms exceeding this 
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threshold are indicated with red dots, whereas single-nucleotide polymorphisms with a P < 
10−4 and >5.0 × 10−8 are indicated with yellow dots.
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Figure 2. Regional Association Plots Across Loci Identified by the Genome-Wide Association 
Study of Myasthenia Gravis
Regional association plots of the signals at the major histocompatibility complex (MHC) 
region (A) and CTLA4 (B) in all myasthenia gravis cases (972 cases and 1977 control 
individuals), as well as the MHC region in early-onset myasthenia gravis cases (C; 235 cases 
and 1977 control individuals), the MHC region in late-onset cases (D), and TNFRSF11A in 
late-onset myasthenia gravis cases (E; 737 cases and 1977 control individuals). Single-
nucleotide polymorphisms are colored on the basis of their linkage disequilibrium with the 
labeled hit single-nucleotide polymorphism. Recombination rates estimated from the CEU 
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HapMap population are represented by the blue line and genes are marked as arrows. Red 
diamonds represent the most associated single-nucleotide polymorphism in the discovery 
cohort and blue diamonds, P values for the combined discovery and replication cohorts. F, 
CTLA4 regulates T-cell activation by antigen-presenting cells (APCs). TCR indicates T-cell 
receptor.
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